Connor, Clark & Lunn Investment Management (CC&L)
RDY icon

Connor, Clark & Lunn Investment Management (CC&L)’s Dr. Reddy's Laboratories RDY Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.3M Buy
382,976
+8,724
+2% +$121K 0.01% 671
2025
Q4 		$5.25M Buy
+374,252
New +$5.25M 0.01% 631
2025
Q2 		– Sell
-31,814
Closed -$420K – 1655
2025
Q1 		$420K Sell
31,814
-273,825
-90% -$3.78M ﹤0.01% 1183
2024
Q4 		$4.83M Sell
305,639
-471,766
-61% -$7.09M 0.02% 491
2024
Q3 		$12.4M Buy
777,405
+533,980
+219% +$8.59M 0.06% 232
2024
Q2 		$3.71M Sell
243,425
-55,600
-19% -$797K 0.02% 501
2024
Q1 		$4.39M Sell
299,025
-21,525
-7% -$314K 0.02% 464
2023
Q4 		$4.46M Sell
320,550
-67,670
-17% -$905K 0.02% 456
2023
Q3 		$5.19M Sell
388,220
-124,245
-24% -$1.68M 0.03% 388
2023
Q2 		$6.47M Buy
512,465
+159,845
+45% +$1.87M 0.03% 340
2023
Q1 		$4.01M Sell
352,620
-474,300
-57% -$5.12M 0.02% 411
2022
Q4 		$8.56M Buy
826,920
+285,720
+53% +$3.08M 0.05% 252
2022
Q3 		$5.67M Buy
541,200
+12,860
+2% +$137K 0.04% 300
2022
Q2 		$5.85M Buy
528,340
+183,945
+53% +$2M 0.04% 279
2022
Q1 		$3.84M Sell
344,395
-28,155
-8% -$319K 0.02% 371
2021
Q4 		$4.87M Buy
372,550
+33,860
+10% +$427K 0.02% 344
2021
Q3 		$4.41M Buy
338,690
+103,085
+44% +$1.37M 0.02% 364
2021
Q2 		$3.46M Buy
235,605
+6,030
+3% +$84.3K 0.02% 432
2021
Q1 		$2.82M Buy
229,575
+163,970
+250% +$2.11M 0.02% 480
2020
Q4 		$935K Buy
+65,605
New +$883K 0.01% 639
2020
Q3 		– Sell
-81,860
Closed -$868K – 1089
2020
Q2 		$868K Sell
81,860
-68,390
-46% -$696K 0.01% 641
2020
Q1 		$1.21M Sell
150,250
-284,000
-65% -$2.37M 0.01% 524
2019
Q4 		$3.52M Buy
434,250
+287,750
+196% +$2.27M 0.02% 329
2019
Q3 		$1.11M Buy
146,500
+90,500
+162% +$673K 0.01% 525
2019
Q2 		$420K Sell
56,000
-11,500
-17% -$90.4K ﹤0.01% 758
2019
Q1 		$547K Buy
+67,500
New +$513K ﹤0.01% 651
2018
Q4 		– Sell
-100,300
Closed -$694K – 1034
2018
Q3 		$694K Buy
100,300
+37,300
+59% +$249K ﹤0.01% 633
2018
Q2 		$406K Buy
+63,000
New +$397K ﹤0.01% 810

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $345M AUM 10.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RDY Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Dr. Reddy's Laboratories (RDY) stake by 2.3% in Q1 2026, buying an estimated $121K and bringing the position to 382,976 shares worth $5.3M. The position accounts for 0.01% of the portfolio, ranked #671.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RDY in Q2 2018 and has held it in 28 quarters since. The position peaked at $12.4M in Q3 2024. 248 funds tracked by Wall St. Rank hold RDY as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 382,976 shares of Dr. Reddy's Laboratories worth $5.3M as of Q1 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 8,724 Dr. Reddy's Laboratories shares in Q1 2026, an estimated $121K.
  • Dr. Reddy's Laboratories made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #671 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Dr. Reddy's Laboratories in Q2 2018 and has held it in 28 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Dr. Reddy's Laboratories position peaked at $12.4M in Q3 2024.
  • 248 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.